Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals)

N/A

Report date: 2023/11/10 18:03:32

Base Information

Drug NameAnti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals)
Drug Alias NameAllogeneic CD19-directed Chimeric Antigen Receptor T (alloCAR-T) cells therapyAllogeneic Second-generation CD19-CAR T Cells therapy (Bellicum Pharmaceuticals)BPX-401
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived +[4] 
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBellicum Pharmaceuticals IncOspedale Pediatrico Bambino Gesu
China Registration ClassN/A

Develop Information

Active CompaniesOspedale Pediatrico Bambino GesuBellicum Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsLymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A